Sukhpreet Klaire
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Sukhpreet Klaire has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
Christy Sutherland
British Columbia Centre on Substance Use (Klaire, Kerr, Kennedy); Département de médecine familiale (Klaire, Sutherland), Université de la Colombie-Britannique; PHS Community Services Society (Klaire, Sutherland); Département de médecine (Kerr), Université de la Colombie-Britannique, Vancouver, C.-B.; School of Social Work (Kennedy), Université de la Colombie-Britannique (Okanagan), Kelowna, C.-B
2 shared publicationsMary Clare Kennedy
British Columbia Centre on Substance Use (Klaire, Kerr, Kennedy); Département de médecine familiale (Klaire, Sutherland), Université de la Colombie-Britannique; PHS Community Services Society (Klaire, Sutherland); Département de médecine (Kerr), Université de la Colombie-Britannique, Vancouver, C.-B.; School of Social Work (Kennedy), Université de la Colombie-Britannique (Okanagan), Kelowna, C.-B
2 shared publicationsThomas Kerr
British Columbia Centre on Substance Use (Klaire, Kerr, Kennedy); Département de médecine familiale (Klaire, Sutherland), Université de la Colombie-Britannique; PHS Community Services Society (Klaire, Sutherland); Département de médecine (Kerr), Université de la Colombie-Britannique, Vancouver, C.-B.; School of Social Work (Kennedy), Université de la Colombie-Britannique (Okanagan), Kelowna, C.-B
2 shared publicationsAndrea Ryan
From the Division of Addiction Medicine, Providence Health Care, Vancouver, British Columbia, Canada (SK, NF, AR, SN, MM, PB); Department of Family Practice, University of British Columbia, Vancouver, British Columbia, Canada (SK, AR, MM); British Columbia Centre on Substance Use, Vancouver, British Columbia, Canada (SK, AK, NF, SN, PB); Division of Social Medicine, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada (NF, SN, PB)
1 shared publication- Ashish P. Thakrar
Division of General Internal Medicine University of Pennsylvania Perelman School of Medicine Philadelphia PA USA
1 shared publication Bernard L. E. Foll
Department of Pharmacology and Toxicology Faculty of Medicine, University of Toronto Toronto Canada
1 shared publication
Latest Publications
Safety and effectiveness of rapid methadone titration protocols in opioid use disorder: A systematic review
Background and aims: Methadone is an effective, first‐line treatment for opioid use disorder. Guidelines recommend slow titration to minimize the risk of methadone toxicity, a process exposing patients to sub‐therapeutic doses for weeks to months. Protocols that titrate more rapidly reduce the time to achieving a therapeutic dose. This systematic review evaluated the safety and effectiveness of rapid methadone titrations in patients with opioid use disorder. Method: Systematic review of prospective and retrospective studies of patients undergoing rapid methadone titration for treatment of opioid use disorder. Both outpatient and inpatient/acute settings were included. Results: A total of 4297 records were screened from MEDLINE, EMBASE, Cochrane CENTRAL and PsycINFO. Following the initial screen, 79 texts were reviewed in full, with 29 studies included in the review, representing 16 154 participants. A wide variety of rapid titration schedules were described across inpatient and outpatient settings. A common protocol (6 studies) started at 30–40 mg, with additional 10 mg every 3–4 hours as needed up to 50–80 mg on day 1. Average dose on day 7 ranged from 53 to 97 mg across 5 randomised controlled trials/cohort studies ( n = 14 758) and from 60 to 200 mg in 5 case series/case reports ( n = 124). Among 26 studies reporting on mortality ( n = 1431), there were 63 deaths in 3 outpatient studies over 2–180 days after starting methadone; 61 deaths were from 2 case series that specifically selected cases of death from coroner reports. Among all 18 studies conducted in the fentanyl era (post‐2013, n = 705), and all 18 inpatient studies from any time period ( n = 604) reporting on mortality, there were no deaths reported. Overdose rates were less than 1% across all studies and sedation events were often mild, with most patients continuing methadone. One study found a correlation between improved retention rates and higher methadone doses during the first week of initiation. Pooled analysis could not be performed due to substantial heterogeneity across studies. Summary: A wide range of rapid methadone titration protocols for opioid use disorder are described in the literature, with generally low‐quality evidence and little standardization in protocols or evaluations. Overall adverse events were rare, particularly with rapid methadone titration in the fentanyl era and during inpatient admissions. Data on retention in treatment and changes in unregulated drug use were limited.
Safety and effectiveness of rapid methadone titration protocols in opioid use disorder: A systematic review
Background and aims: Methadone is an effective, first‐line treatment for opioid use disorder. Guidelines recommend slow titration to minimize the risk of methadone toxicity, a process exposing patients to sub‐therapeutic doses for weeks to months. Protocols that titrate more rapidly reduce the time to achieving a therapeutic dose. This systematic review evaluated the safety and effectiveness of rapid methadone titrations in patients with opioid use disorder. Method: Systematic review of prospective and retrospective studies of patients undergoing rapid methadone titration for treatment of opioid use disorder. Both outpatient and inpatient/acute settings were included. Results: A total of 4297 records were screened from MEDLINE, EMBASE, Cochrane CENTRAL and PsycINFO. Following the initial screen, 79 texts were reviewed in full, with 29 studies included in the review, representing 16 154 participants. A wide variety of rapid titration schedules were described across inpatient and outpatient settings. A common protocol (6 studies) started at 30–40 mg, with additional 10 mg every 3–4 hours as needed up to 50–80 mg on day 1. Average dose on day 7 ranged from 53 to 97 mg across 5 randomised controlled trials/cohort studies ( n = 14 758) and from 60 to 200 mg in 5 case series/case reports ( n = 124). Among 26 studies reporting on mortality ( n = 1431), there were 63 deaths in 3 outpatient studies over 2–180 days after starting methadone; 61 deaths were from 2 case series that specifically selected cases of death from coroner reports. Among all 18 studies conducted in the fentanyl era (post‐2013, n = 705), and all 18 inpatient studies from any time period ( n = 604) reporting on mortality, there were no deaths reported. Overdose rates were less than 1% across all studies and sedation events were often mild, with most patients continuing methadone. One study found a correlation between improved retention rates and higher methadone doses during the first week of initiation. Pooled analysis could not be performed due to substantial heterogeneity across studies. Summary: A wide range of rapid methadone titration protocols for opioid use disorder are described in the literature, with generally low‐quality evidence and little standardization in protocols or evaluations. Overall adverse events were rare, particularly with rapid methadone titration in the fentanyl era and during inpatient admissions. Data on retention in treatment and changes in unregulated drug use were limited.
- Open Access
- 18 June 2026
- Published by Wiley in Drug and Alcohol Review
- Vol. 45 (5) , e70190
Differential Impacts of Methadone and Buprenorphine/Naloxone on Pain‐Related Outcomes Among People With Non‐Heroin Opioid Use Disorder: Secondary Analyses From a Pragmatic Canadian Multisite Trial
Introduction: In addition to their use as opioid agonist therapy (OAT), methadone and buprenorphine/naloxone also have analgesic properties. However, there is limited information on the relative effectiveness of these medications for analgesia in the context of treatment for non‐heroin opioid use disorder (OUD). This study estimated the impact of type of OAT on pain among individuals with non‐heroin OUD. Methods: Using data from OPTIMA, a Canadian, randomised, 24‐week clinical trial comparing buprenorphine/naloxone (via take‐home doses) to methadone (via daily witnessed ingestion) for the treatment of non‐heroin OUD, we evaluated the impact of type of OAT on pain outcomes (measured by the Brief Pain Inventory) among participants with major pain at baseline. Results: Mean pain severity scores significantly decreased in both arms over 24 weeks (methadone 4.89–2.16, buprenorphine/naloxone 4.94–1.08). There was a time by arm interaction, suggesting better performance of buprenorphine/naloxone up to week 9, and methadone afterwards. Mean pain‐related function scores also significantly decreased over time (methadone 5.31–2.70, buprenorphine/naloxone 5.56–3.37), with no significant differences in overall scores between arms ( p = 0.675). Methadone was associated with higher odds of achieving both pain severity and pain‐related function response at week 24 (30% reduction in pain scores from baseline). Discussion and Conclusions: Among people with non‐heroin OUD initiating OAT, both methadone and buprenorphine/naloxone were associated with improvements in pain outcomes. However, methadone was associated with a higher likelihood of achieving pain severity and functional treatment response at week 24. These findings suggest the need to consider the type of OAT in the shared‐decision making process for people with non‐heroin OUD and comorbid pain.
- 18 June 2026
- Published by Wiley in Drug and Alcohol Review
- Vol. 45 (5) , e70190
Open AccessDifferential Impacts of Methadone and Buprenorphine/Naloxone on Pain‐Related Outcomes Among People With Non‐Heroin Opioid Use Disorder: Secondary Analyses From a Pragmatic Canadian Multisite Trial
Introduction: In addition to their use as opioid agonist therapy (OAT), methadone and buprenorphine/naloxone also have analgesic properties. However, there is limited information on the relative effectiveness of these medications for analgesia in the context of treatment for non‐heroin opioid use disorder (OUD). This study estimated the impact of type of OAT on pain among individuals with non‐heroin OUD. Methods: Using data from OPTIMA, a Canadian, randomised, 24‐week clinical trial comparing buprenorphine/naloxone (via take‐home doses) to methadone (via daily witnessed ingestion) for the treatment of non‐heroin OUD, we evaluated the impact of type of OAT on pain outcomes (measured by the Brief Pain Inventory) among participants with major pain at baseline. Results: Mean pain severity scores significantly decreased in both arms over 24 weeks (methadone 4.89–2.16, buprenorphine/naloxone 4.94–1.08). There was a time by arm interaction, suggesting better performance of buprenorphine/naloxone up to week 9, and methadone afterwards. Mean pain‐related function scores also significantly decreased over time (methadone 5.31–2.70, buprenorphine/naloxone 5.56–3.37), with no significant differences in overall scores between arms ( p = 0.675). Methadone was associated with higher odds of achieving both pain severity and pain‐related function response at week 24 (30% reduction in pain scores from baseline). Discussion and Conclusions: Among people with non‐heroin OUD initiating OAT, both methadone and buprenorphine/naloxone were associated with improvements in pain outcomes. However, methadone was associated with a higher likelihood of achieving pain severity and functional treatment response at week 24. These findings suggest the need to consider the type of OAT in the shared‐decision making process for people with non‐heroin OUD and comorbid pain.
- 7 August 2023
- Published by Wolters Kluwer Health in Journal of Addiction Medicine
- Vol. 17 (6) , 711-713
Safety and Efficacy of Rapid Methadone Titration for Opioid Use Disorder in an Inpatient Setting: A Retrospective Cohort Study
Objectives: Inpatient guidelines for methadone titration do not exist, whereas outpatient guidelines lack flexibility and do not consider individual opioid tolerance. The evaluation of rapid, adaptable titration protocols may allow more patient-centered and effective treatment for opioid use disorder in the fentanyl era. Methods: This study performed a retrospective chart review of patients 18 years or older with opioid use disorder who were initiated on methadone at a single academic urban hospital using a rapid divided dose protocol between November 2019 and November 2020. The primary outcome was adverse events associated with methadone, specifically opioid toxicity or sedation requiring increased medical observation or intervention. The secondary outcome was total daily dose of methadone received on day 7 of titration. Results: Ninety-eight patients were included for a total of 168 visits. Sixty-five (66%) were male, with a median age of 38 years (interquartile range, 31–42 years). Sedation occurred in 2 patients (1%), who required either naloxone administration or transfer to an intensive care unit for monitoring. Of the 135 visits where patients received at least 7 days of methadone, the mean dose on day 1 was 41 mg (SD, 9.6 mg) and on day 7 was 65 mg (SD, 20.9 mg). Conclusions: In this inpatient cohort, rapid methadone titration was well tolerated and resulted in patients reaching higher doses of methadone than would be possible with a standard schedule, with few adverse events. Given the known effective dose range, this approach may result in shorter time to clinical stabilization and suggests that alternative methadone titration schedules may be safe and effective in appropriately selected patients.
- 7 August 2023
- Published by Wolters Kluwer Health in Journal of Addiction Medicine
- Vol. 17 (6) , 711-713
Safety and Efficacy of Rapid Methadone Titration for Opioid Use Disorder in an Inpatient Setting: A Retrospective Cohort Study
Objectives: Inpatient guidelines for methadone titration do not exist, whereas outpatient guidelines lack flexibility and do not consider individual opioid tolerance. The evaluation of rapid, adaptable titration protocols may allow more patient-centered and effective treatment for opioid use disorder in the fentanyl era. Methods: This study performed a retrospective chart review of patients 18 years or older with opioid use disorder who were initiated on methadone at a single academic urban hospital using a rapid divided dose protocol between November 2019 and November 2020. The primary outcome was adverse events associated with methadone, specifically opioid toxicity or sedation requiring increased medical observation or intervention. The secondary outcome was total daily dose of methadone received on day 7 of titration. Results: Ninety-eight patients were included for a total of 168 visits. Sixty-five (66%) were male, with a median age of 38 years (interquartile range, 31–42 years). Sedation occurred in 2 patients (1%), who required either naloxone administration or transfer to an intensive care unit for monitoring. Of the 135 visits where patients received at least 7 days of methadone, the mean dose on day 1 was 41 mg (SD, 9.6 mg) and on day 7 was 65 mg (SD, 20.9 mg). Conclusions: In this inpatient cohort, rapid methadone titration was well tolerated and resulted in patients reaching higher doses of methadone than would be possible with a standard schedule, with few adverse events. Given the known effective dose range, this approach may result in shorter time to clinical stabilization and suggests that alternative methadone titration schedules may be safe and effective in appropriately selected patients.
- Open Access
- 15 August 2022
- Published by CMA Impact Inc. in Canadian Medical Association Journal
- Vol. 194 (31) , E1098-E1100
Un programme d’approvisionnement sécuritaire, souple et peu restrictif pour prévenir les décès par surdose
- 15 August 2022
- Published by CMA Impact Inc. in Canadian Medical Association Journal
- Vol. 194 (31) , E1098-E1100
Open AccessUn programme d’approvisionnement sécuritaire, souple et peu restrictif pour prévenir les décès par surdose
- Open Access
- 4 June 2022
- Published by Elsevier in International Journal of Drug Policy
- Vol. 106, 103741
Take-home drug checking as a novel harm reduction strategy in British Columbia, Canada
- 4 June 2022
- Published by Elsevier in International Journal of Drug Policy
- Vol. 106, 103741
Open AccessTake-home drug checking as a novel harm reduction strategy in British Columbia, Canada
- Open Access
- 16 May 2022
- Published by CMA Impact Inc. in Canadian Medical Association Journal
- Vol. 194 (19) , E674-E676
A low-barrier, flexible safe supply program to prevent deaths from overdose
- 16 May 2022
- Published by CMA Impact Inc. in Canadian Medical Association Journal
- Vol. 194 (19) , E674-E676
Open AccessA low-barrier, flexible safe supply program to prevent deaths from overdose